New anticoagulant drugs: a turning point in oral anticoagulation management?

D. Prisco\textsuperscript{a,b}, E. Grifoni\textsuperscript{a}, D. Poli\textsuperscript{b}

\textsuperscript{a}Dipartimento di Area Critica Medico Chirurgica, Università degli Studi di Firenze;  
\textsuperscript{b}Centro Trombosi, DAI del Cuore e dei Vasi, Azienda Ospedaliero-Universitaria Careggi, Firenze

Summary

Heparins and vitamin K antagonists have been the cornerstones of anticoagulant therapy for several decades. Although effective, currently available agents have limitations that have prompted the search for new drugs matching the “ideal” anticoagulant profile. At present, agents targeting factor Xa and thrombin are in the most advanced stages of clinical development. With potential advantages including predictable pharmacological profile, rapid onset of action, low propensity for food and drug interactions, administration of fixed doses and no requirement for therapeutic monitoring, these new agents may potentially improve the management of thromboembolic disorders. However, potential challenges of bringing new anticoagulants to the clinic should be taken into account.

Key-words: new anticoagulants, factor Xa inhibitors, direct thrombin inhibitors.

Introduction

Currently available anticoagulant drugs include both parenteral and oral agents. Rapidly acting parenteral anticoagulants are commonly used for initial treatment of arterial or venous thromboembolic diseases, whereas oral agents are employed for long-term therapy. Low-molecular-weight heparins (LMWH) have replaced unfractioned heparin (UFH) for most indications because they are more convenient to administer and meta-analyses of clinical trials comparing LMWH with UFH indicate that they are at least as effective and safe. More recently, fondaparinux, a synthetic indirect inhibitor of factor Xa, obtained the licence for venous thromboembolism (VTE) prevention in high-risk orthopaedic surgery patients and, in some countries among which Italy, in general surgical or medical patients. Fondaparinux is also licensed as an alternative to UFH or LMWH for initial treatment of VTE and for patients with acute coronary syndromes. Although LMWH and fondaparinux are important advances, some difficulties persist. The need for once or twice-daily subcutaneous injections renders treatment problematic for some patients\textsuperscript{1}. This has prompted the development of longer acting parenteral anticoagu-
lants that can be given subcutaneously on a once-weekly basis, and of novel oral anticoagulants with a rapid onset of action. For over 60 years, vitamin K antagonists (VKAs), such as warfarin, have been the only available oral anticoagulants, despite their many limitations. Their slow onset of action necessitates overlap with a parenteral anticoagulant for at least 5 days. Moreover, they have a narrow therapeutic window and exhibit a considerable variability in dose-response among patients, which reflects, at least in part, differences in dietary vitamin K intake, genetic polymorphisms in the enzymes involved in VKAs metabolism, and administration of concomitant medications that suppress or potentiate the anticoagulant effects of VKAs. Regular coagulation monitoring and dose adjustments are therefore necessary to ensure that a therapeutic anticoagulant response is achieved. The need for frequent coagulation monitoring is burdensome for patients and physicians and costly for the healthcare system. An “improved” oral anticoagulant at least as effective as VKAs in preventing thrombus formation and at least as safe with respect to bleeding risk would be highly desirable. The properties of such an “ideal” agent include a wide therapeutic window, a predictable dose-response relationship (not requiring laboratory monitoring), a rapid onset and offset of action, a readily available antidote or reversal agent, minimal food and drug interactions, and clear efficacy in large trials without adverse effects.

Recently, dabigatran, an oral direct thrombin inhibitor, has been licensed in Europe for VTE prophylaxis in major orthopaedic surgery, and rivaroxaban, an oral direct factor Xa inhibitor, is expected to be available for the same indication during 2009.

In this article new anticoagulant drugs that are in the most advanced stages of development are reviewed, focusing on: 1) their pharmacology; 2) results of clinical trials evaluating their efficacy and safety; 3) their potential advantages and drawbacks in the management of patients with arterial and venous thromboembolic diseases.

**Targets of new anticoagulant drugs**

When considering candidates for potential new oral anticoagulants, attention must be paid to the three temporal aspects of coagulation, including initiation, propagation, and termination. Most of the so far available anticoagulants inhibit multiple steps in the coagulation cascade, whereas new anticoagulants selectively target one specific coagulation factor. Drugs targeting the tissue factor/factor VIIa complex prevent the initiation of coagulation. The propagation phase can be inhibited by drugs that block factors IXa or Xa, or their respective coenzymes, factors VIIla and Va. Finally, agents targeting thrombin can prevent fibrin formation (Figure 1). Although drugs targeting factor VIIa-tissue factor as well as factor IXa have been developed and undergone initial evaluation in the clinic, agents targeting factor Xa and thrombin are in the most advanced stages of clinical development.

Factor Xa is an attractive target for the design of new anticoagulants as it is positioned at the start of the common pathway of coagulation. When bound to factor Va, in the presence of calcium on a phospholipid bilayer, it forms the prothrombinase complex and catalyzes the conversion of prothrombin to thrombin. Factor Xa is also the primary site of serine protease activity amplification, as one molecule gives origin to approximately 1000 molecules of thrombin. Inhibition of factor Xa can occur through direct binding to the factor Xa active site, or indirectly through interaction with antithrombin. Direct factor Xa inhibitors have an advantage because they can bind both free factor Xa and factor Xa within the prothrombinase complex and, therefore, penetrate active thrombus to limit further thrombin generation.

Thrombin plays a central role as a procoagulant by converting fibrinogen to fibrin as well as by activating its other substrates including factor V, factor VIII, factor XI, factor XIII, and the platelet protease activated receptors (PAR-1 and PAR-4). Direct thrombin inhibition is therefore another attractive antithrombotic strategy. Direct thrombin inhibitors inhibit thrombin by directly binding either to exosite 1 for fibrin or the active site of thrombin or both.

**Pharmacology of new anticoagulants**

Factor Xa inhibitors include indirect inhibitors, such as idraparinux and SSR 126517, parenteral drugs that target factor Xa in an antithrombin-dependent way, and direct inhibitors, such as the orally active agents rivaroxaban and apixaban. Direct thrombin inhibitors include parenteral agents, such as lepirudin, argatroban, and bivalirudin, which have gained approval for limited clinical indications consisting of heparin induced thrombocytopenia and percutaneous coronary in-
Interventions, and orally active drugs, such as dabigatran etexilate (Figure 1). Table I shows a comparison among the pharmacologic properties of new anticoagulant drugs.

**Idraparinux**

Idraparinux, a second generation synthetic pentasaccharide, is a hypermethylated derivative of fondaparinux with a longer plasma half-life (about 80 h). Idraparinux exhibits complete bioavailability after subcutaneous injection, binds only to antithrombin in plasma and produces a predictable anticoagulant response. Consequently, it can be given by subcutaneous injection once-weekly and does not require coagulation monitoring. Like fondaparinux, idraparinux is not metabolized and is excreted unchanged via the kidneys. Therefore, the dose must be reduced in patients with renal insufficiency, and it is contraindicated in those with severe renal impairment. The safety of idraparinux in pregnancy is uncertain. No antidote is available to reverse the anticoagulant activity of idraparinux. In order to address this problem SSR 126517 has been developed. This agent is a biotinylated version of idraparinux, which shares the same pharmacological features. The addition of the biotin moiety permits rapid reversal of the anticoagulant effects of SSR 126517 after intravenous injection of avidin, an egg white-derived protein, which binds biotin with high affinity to form a stable complex that is cleared within minutes via the kidneys.

**Rivaroxaban**

Rivaroxaban, an oxazolidinone derivative, is a potent and selective inhibitor of factor Xa. It binds to the active site of factor Xa and inhibits the enzyme in a reversible and competitive way regardless of whether factor Xa is free in solution or bound within the prothrombinase complex. Rivaroxaban is well absorbed from the gastrointestinal tract with a bioavailability of more than 80%, and food has no major effect on its absorption. Peak plasma levels are achieved in about 3 h. Its terminal half-life is about 5 to 9 h in young individuals, and 11 to 13 h in the elderly. Rivaroxaban exhibits a dual mechanism of excretion: approximately 66% is excreted via the kidneys, and the remainder is excreted in the feces. Intestinal excretion of rivaroxaban appears to be mediated, at least in part, by P-glycoprotein, a transport protein, because potent P-glycoprotein inhibitors increase drug levels. Of that found in the urine, 30% to 40% reflects unchanged drug that is excreted via a combination of glomerular filtration and tubular secretion, whereas the remainder reflects metabolites. Because of its renal clearance, rivaroxaban must be used with caution in patients with renal insufficiency. Rivaroxaban is metabolized in the liver via CYP 3A4, CYP 2J2, and via CYP-independent mechanisms. It is contraindicated in patients with severe liver disease because metabolic inactivation may be impaired. Caution must also be exercised in patients receiving treatment with potent inhibitors of both CYP3A4 and P-glycoprotein, such as ketoconazole or ritonavir, because reduced fecal and renal clearance of rivaroxaban by these drugs can cause an exaggerated anticoagulant effect. Like other direct factor Xa inhibitors, rivaroxaban prolongs prothrombin time (PT) and activated partial thromboplastin time (aPTT), with PT being more sensitive than aPTT depending on the reagents used for testing. However, the effect of the

---

**Table I. Comparative properties of new anticoagulant agents.**

<table>
<thead>
<tr>
<th></th>
<th>Idraparinux</th>
<th>Rivaroxaban</th>
<th>Apixablan</th>
<th>Dabigatran etexilate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target</strong></td>
<td>Factor Xa</td>
<td>Factor Xa</td>
<td>Factor Xa</td>
<td>Thrombin</td>
</tr>
<tr>
<td><strong>Route of administration</strong></td>
<td>Subcutaneous</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Frequency of administration</strong></td>
<td>Once-weekly</td>
<td>Once-daily</td>
<td>Twice-daily</td>
<td>Once or twice-daily</td>
</tr>
<tr>
<td><strong>Prodrug</strong></td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Bioavailability</strong></td>
<td>100%</td>
<td>&gt;80%</td>
<td>&gt;50%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Peak plasma concentration</strong></td>
<td>1-3 h</td>
<td>3 h</td>
<td>3 h</td>
<td>2 h</td>
</tr>
<tr>
<td><strong>Half-life</strong></td>
<td>80 h</td>
<td>9 h</td>
<td>9-14 h</td>
<td>14-17 h</td>
</tr>
<tr>
<td><strong>Mode of excretion</strong></td>
<td>100% renal</td>
<td>66% renal, 34% hepatic</td>
<td>25% renal, 75% hepatic</td>
<td>80% renal, 20% hepatic</td>
</tr>
<tr>
<td><strong>Drug interactions</strong></td>
<td>Potent CYP3A4 and P-glycoprotein inhibitors</td>
<td>Potent CYP3A4 and P-glycoprotein inhibitors</td>
<td>Proton pump inhibitors; potent P-glycoprotein inductors and inhibitors</td>
<td></td>
</tr>
<tr>
<td><strong>Antidote</strong></td>
<td>No*</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Safe in pregnancy</strong></td>
<td>Unknown</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

*Available for biotinylated idraparinux.
drug on these tests is short-lived, with prolongation only seen at peak drug levels. Factor Xa inhibition is the best test to monitor drug concentrations in plasma12.

Apixaban

Apixaban is a selective and reversible inhibitor of factor Xa and, like rivaroxaban, it inhibits factor Xa bound within the prothrombinase complex as well as the free enzyme. The drug is absorbed from the gastrointestinal tract with a bioavailability over 50%, and peak plasma levels are achieved in about 3 h. With repeated doses, the terminal half-life is between 9 and 14 h. Apixaban is metabolized in the liver via CYP3A4 and via CYP-independent mechanisms. It exhibits a dual mechanism of excretion, with about 25% being excreted via the kidneys, whereas the remainder appears in the faeces. Apixaban prolongs International Normalized Ratio (INR) and aPTT in a concentration-dependent way. However, its effect on these tests is minimal at therapeutic concentrations. It can be monitored using a factor Xa inhibition assay or a dilute PT13.

Dabigatran etexilate

Dabigatran etexilate is an oral prodrug that, once absorbed from the gastrointestinal tract, is converted by esterases into its active metabolite, dabigatran, a competitive and reversible direct thrombin inhibitor14. Because bioconversion of dabigatran etexilate to dabigatran begins in the gut, the drug enters the portal vein as a combination of prodrug and active compound. Once in the liver, bioconversion of the prodrug is completed and about 20% is conjugated and excreted via the biliary system. The cytochrome P450 system plays no part in the metabolism of dabigatran etexilate. Therefore, the risk of drug-drug interactions is low15. Because the bioavailability of dabigatran etexilate is only about 6%, relatively high doses of dabigatran etexilate must be given to ensure that adequate plasma concentrations are achieved. The absorption of dabigatran etexilate in the stomach and small intestine is dependent on an acid environment. To promote such a microenvironment, dabigatran etexilate is provided in tartaric acid-containing capsules. Drug absorption is reduced by 20% to 25% if dabigatran treated patients are given proton pump inhibitors. Peak plasma levels of dabigatran are achieved about 2 h after dabigatran etexilate administration. The half-life of dabigatran is approximately 8 h after single dose administration and up to 14 to 17 h after multiple doses. About 80% of circulating dabigatran is excreted unchanged via the kidneys. Consequently, plasma concentrations increase in patients with renal insufficiency and the drug is contraindicated in patients with renal failure. Dabigatran etexilate prolongs aPTT, but its effects on this test are not dose-dependent. It has minimal effect on PT but prolongs ecarin clotting time in a concentration-dependent way16,17.

Clinical studies with new anticoagulants

Idraparinux has completed phase III clinical trials for VTE treatment, and trials with its biotinylated form SR 126517 are underway. Phase II trials with rivaroxaban, apixaban, and dabigatran etexilate have been completed, and phase III trials with all three agents are some finished and some ongoing.

Idraparinux

Idraparinux has been evaluated in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), the extended secondary prophylaxis of VTE, and the long-term prevention of stroke in patients with atrial fibrillation. The phase III Van Gogh trials compared subcutaneous idraparinux at a dose of 2.5 mg once-weekly with LMWH or UFH followed by 3 or 6 months of a VKA for the treatment of patients with DVT or PE18. In the DVT patients, the primary efficacy outcome, the rate of recurrent VTE at 3 months, was similar in the idraparinux and conventionally-treated groups (2.9% and 3.0%, respectively). At 3 months, clinically relevant bleeds were less common with idraparinux than with conventional treatment (4.5% and 7.0%, respectively; p=0.004). In the PE patients, idraparinux was less effective than conventional anticoagulant therapy at 3 months. Thus, the rate of recurrent VTE was 3.4% in those treated with idraparinux and 1.6% in those given conventional therapy. Rates of clinically relevant bleeding at 3 months in patients treated with idraparinux or conventional anticoagulant therapy were 5.8% and 8.2%, respectively. The discordant efficacy results in the DVT and PE trials highlight the importance of adequate levels of anticoagulation for initial treatment of PE because the majority of recurrences occurred early in idraparinux-treated patients. These findings suggest that PE patients require higher initial doses of idraparinux than DVT patients; however, the safety of higher dose treatment remains to be established. The efficacy of long-term idraparinux therapy was evaluated in the Van Gogh extension trial, which enrolled patients from the DVT or PE trials who had received 6 months of treatment with either idraparinux or a VKA19. Patients were randomized to an additional 6 months of treatment with either subcutaneous idraparinux at a dose of 2.5 mg once-weekly or placebo. Compared with placebo, idraparinux was effective in reducing the rate of recurrent VTE (from 3.7% to 1.0%; p=0.002), but was associated with an increased risk of major bleeding (1.9% in the idraparinux group, including 3 fatal intracranial bleeds, vs none in the placebo group; p<0.001)19. The Amadeus trial in patients with atrial fibrillation was stopped after randomization of 4576 patients because of a significantly increased number of clinically relevant bleeds and intracranial bleeds with idraparinux in comparison with
VKAs (19.7% vs. 11.3% and 1.1% vs. 0.4%, respectively)\textsuperscript{20}. Consequently, SSR 126517 has been developed. It is unclear, however, whether rendering idraparinux reversible through biotinylation will improve the benefit-to-risk profile of the drug. The bioequipotency of SSR 126517 in comparison with an equimolar dose of idraparinux has been evaluated in a clinical trial addressing the treatment of symptomatic DVT without symptomatic PE (EQUINOX trial). Currently, SSR 126517 is also under investigation in patients with symptomatic PE who are administered an initial treatment with enoxaparin (CASSIOPEA trial). Finally, a SSR 1265517 dose regimen adjusted to patient characteristics (age and renal function), which might preserve efficacy without an increased haemorrhagic risk, is presently being evaluated in patients with atrial fibrillation (BOREALIS-AF trial).

**Rivaroxaban**

To date, the efficacy and safety of rivaroxaban for the prophylaxis and treatment of VTE has been evaluated in phase II and phase III trials involving over 24,000 patients. Additionally, rivaroxaban is being evaluated for the treatment of PE, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with atrial fibrillation. Four phase III clinical trials, the RECORD 1-4 studies, were designed to evaluate the effectiveness of rivaroxaban administered at a dose of 10 mg once-daily starting 6-8 h postoperatively in the prevention of VTE in patients undergoing major orthopaedic surgery\textsuperscript{21-24}. The RECORD 1 and 2 trials, which studied patients undergoing total hip replacement, compared rivaroxaban administered for 5 weeks with enoxaparin 40 mg administered once-daily starting the evening before surgery for 5 weeks (RECORD 1)\textsuperscript{24} or for 10-14 days followed by placebo (RECORD 2)\textsuperscript{22}. In the RECORD 3 and 4 trials, patients undergoing total knee replacement were randomized to receive prophylaxis for 10-14 days with postoperative rivaroxaban or with enoxaparin 40 mg once-daily starting the evening before surgery (RECORD 3)\textsuperscript{23}, or enoxaparin 30 mg twice-daily starting 12-24 h after surgery (RECORD 4)\textsuperscript{24}. All four studies demonstrated that rivaroxaban was significantly more effective than enoxaparin in VTE prophylaxis following total hip or knee replacement. The incidence of major and non-major bleeding events was similar between the two comparator groups in each of the four trials. A pooled analysis was performed on all randomized patients who received at least one dose of double-blind study medication to evaluate the effect of rivaroxaban on the composite of symptomatic VTE (comprising DVT or PE) and death, and bleeding\textsuperscript{25}. These primary outcomes were analyzed at day 12±2 in the active treatment pool (i.e., during the enoxaparin-controlled period common to all studies, to allow for unbiased comparison of rivaroxaban with enoxaparin), and for the total study duration pool (planned treatment period and 30-35 days follow-up). This analysis demonstrated that in the regimens tested, rivaroxaban reduced the composite of major clinical outcomes compared with enoxaparin regimens, with no significant increase in the risk of major bleeding in patients undergoing major orthopaedic surgery\textsuperscript{25}. The utility of rivaroxaban for VTE treatment was assessed in two phase II studies. The ODIXa-DVT study randomized 613 patients with symptomatic proximal DVT without PE to a 3-month course of rivaroxaban (at doses of 10, 20, or 30 mg once-daily or 40 mg twice-daily) or to LMWH followed by warfarin\textsuperscript{26}. The primary efficacy outcome, a reduction in thrombus burden based on improvement in the results of repeated ultrasound evaluation at 21 days and no evidence of recurrent VTE, was achieved in 43.8% to 59.2% of those given rivaroxaban and in 45.9% of those given conventional anticoagulant therapy. The incidence of major and minor bleeding increased with escalating doses of rivaroxaban (range: 5.0%-11.6%) compared with patients treated with LMWH/warfarin (6.3%)\textsuperscript{26}. The Einstein-DVT study randomized 543 patients with symptomatic proximal DVT without PE to a 3-month course of once-daily rivaroxaban (at doses of 20, 30, or 40 mg) or to conventional anticoagulant therapy\textsuperscript{27}. The primary efficacy end point, a composite of symptomatic recurrent VTE plus an increase in thrombus burden (as detected by repeated ultrasound examination and perfusion lung scanning), occurred in 6% of those randomized to rivaroxaban and in 9.9% of those given conventional therapy. The incidence of clinical relevant bleeding occurred in 2.2%-6.0% of patients in rivaroxaban groups and in 8.8% of patients in LMWH/warfarin group, with no significant dose-response for bleeding\textsuperscript{27}. There was no apparent dose-response for efficacy with rivaroxaban in either trials. However, the dose-dependent increase in the risk of bleeding was reported in the ODIXa-DVT study indicating that twice-daily regimen for rivaroxaban might increase risk of bleeding. Based on the results of these trials, phase III trials evaluating rivaroxaban for initial and extended treatment of VTE and for the prevention of stroke in atrial fibrillation (ROCKET-AF) are using the 20 mg once-daily dose.

**Apixaban**

At present, the efficacy and safety of apixaban for the prophylaxis and treatment of VTE is being evaluated in phase II and phase III trials involving nearly 25,000 patients. Trials are also underway involving over 20,000 patients for secondary prevention after acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. In the phase II APPROPOS trial, apixaban prevented more cases of DVT, PE and death after total knee replacement than enoxaparin, but the risk of bleeding correlated with drug dose\textsuperscript{28}. In the phase II Botticelli-DVT trial, 520 patien-
ts with proximal DVT were randomized to a 3-month course of treatment with apixaban (at doses of 5 or 10 mg twice-daily or 20 mg once-daily) or to conventional anticoagulant therapy with LMWH or fondaparinux followed by a VKA. The primary efficacy end point, a composite of recurrent VTE and increased thrombus burden (as detected by repeated ultrasound and perfusion lung scanning), occurred in 6.0%, 5.6%, and 2.6% of patients given apixaban at doses of 5 or 10 mg twice-daily or 20 mg once-daily, respectively, and in 4.2% of those treated with conventional therapy. Rates of major plus clinically relevant non-major bleeding were 8.6%, 4.5%, and 7.3% in the apixaban arms, respectively, and 7.9% in those given conventional treatment. Based on these results, phase III trials are evaluating both a 2.5 and a 5 mg twice-daily regimen of apixaban for initial and extended treatment of VTE. Apixaban was also tested as an additional treatment for patients with acute coronary syndromes in the phase II APPRAISE-1 safety study. Being administered in combination with currently recommended antiplatelet therapy, apixaban appeared to be safer in low dose (2.5 mg twice-daily), while the 10 mg twice-daily and 20 mg once-daily arms were stopped early due to increased total bleeding. On the basis of results of the phase II trials, other phase II and III trials are ongoing. The ADOPT study is investigating once-daily apixaban of 2.5 mg for one month compared to enoxaparin for the prevention of VTE in medically ill patients. The three ADVANCE studies are investigating the efficacy and safety of apixaban (2.5 mg twice-daily) compared with enoxaparin in patients undergoing major orthopaedic surgery. The preliminary results for ADVANCE-1 failed to show (statistical) non-inferiority when compared with enoxaparin. AVERROES and ARISTOTLE are both phase III trials on stroke prevention in atrial fibrillation patients. The three ADVANCE studies are investigating apixaban against aspirin in a superiority trial of stroke prevention among patients with atrial fibrillation at moderate risk or in whom VKAs are contraindicated or refused, whereas ARISTOTLE is a phase III non-inferiority trial comparing apixaban with warfarin for stroke prevention in high-risk patients with atrial fibrillation.

**Dabigatran etexilate**

Phase II and III clinical trials assessing dosages, efficacy and tolerability in numerous indications including VTE prevention and treatment, stroke prevention in atrial fibrillation, and secondary prevention of cardiac events in patients with acute coronary syndromes have been conducted or are underway with dabigatran etexilate. To date, two phase II dose-ranging studies and three phase III clinical trials have been completed for the evaluation of dabigatran etexilate in VTE prevention in patients undergoing orthopaedics surgery. In the BISTRO I study, dabigatran etexilate demonstrated an acceptable safety therapeutic profile with doses ranging from 12.5 to 300 mg twice-daily in patients undergoing elective total hip replacement. There were bleeding events in two patients, who had a lower creatinine clearance (<50 ml/min) on the higher doses of 300 mg twice-daily. Subsequently, in the BISTRO II study (dabigatran etexilate compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement) four different doses of dabigatran etexilate were compared with enoxaparin, with a significant reduction in VTE events in patients receiving 150 mg twice-daily, 300 mg once-daily and 225 mg twice-daily, with an increase in major bleeding observed in the 300 mg once-daily dose (4.7%). The RE-MODEL trial in patients undergoing total knee replacement compared 75 or 110 mg of dabigatran etexilate starting 1-4 h postoperatively followed by 150 or 220 mg once-daily, respectively, with enoxaparin 40 mg 12 h before surgery and then once-daily starting 12–24 h postoperatively. The primary efficacy outcome (the composite of total VTE, proximal and distal DVT demonstrated by mandatory bilateral venography, symptomatic VTE, and all-cause mortality during the treatment period of 6-10 days) occurred at similar rates in patients receiving the two doses of dabigatran etexilate (36.4% in the 220 mg group and 40.5% in the 150 mg group) or enoxaparin (37.7%); both doses of the oral agent met the prespecified criterion for non-inferiority. The rates of the major safety endpoint and major bleeding were low and similar in the three groups, and no significant differences in liver enzyme elevations were observed. The RE-NOVATE trial demonstrated that the 150 or 220 mg doses of dabigatran etexilate were non-inferior to the 40 mg enoxaparin regimen for the extended prevention (28–35 days) of VTE following total hip replacement. Another phase III trial of dabigatran etexilate for VTE prophylaxis following total knee replacement, RE-MOBILIZE, used the same doses of drug as the RE-MODEL trial, but the initial half-dose was administered 6-12 h postoperatively and the comparator, enoxaparin at a dose of 30 mg twice-daily, was only administered postoperatively, which is the preferred schedule in North America. The primary endpoint was the same as in the RE-MODEL trial, but dabigatran etexilate at 150 and 220 mg doses had VTE rates of 33.7% and 31.1%, respectively, which were significantly higher than the enoxaparin regimen (25.3%). Hence, in the RE-MOBILIZE trial dabigatran etexilate did not demonstrate non-inferiority as compared with the North American enoxaparin regimen. A meta-analysis of efficacy and safety data for the recommended dose of dabigatran etexilate, 220 mg once-daily, for VTE prophylaxis after major orthopaedic surgery was performed combining RE-MODEL and RE-NOVATE, and also including RE-MOBILIZE. No significant differences were detected between dabigatran etexilate and enoxaparin in any of the end-points analyzed, either in the two trial analysis.
New anticoagulants: potential advantages and challenges in anticoagulation management

Selective inhibitors of factor Xa and thrombin have the potential to be more effective, safer and easier to use than the currently available anticoagulant drugs. The greatest unmet need in anticoagulation therapy is replacement of VKAs with an orally active agent that can be given in fixed doses without routine coagulation monitoring. Consequently, most of the current attention is focused on new oral anticoagulants. All of the new oral inhibitors of factor Xa or thrombin have a rapid onset of action with peak plasma levels achieved within 2 to 4 h. Thus, these new agents have the potential to avoid the need for parenteral anticoagulants in the initial phase of treatment. With a predictable pharmacological profile that allows fixed dosing, low propensity for food and drug interactions and no need for coagulation monitoring, new oral anticoagulants may also offer advantages over VKAs for extended VTE therapy of for long-term use in a chronic condition such as atrial fibrillation. While formal cost-effectiveness analyses are not yet available, avoidance of the intensive, costly, and frequent coagulation monitoring required with VKAs as well as a lower potential for dose-adjustment errors with consequent potential reduction in adverse vascular events precipitated by the narrow therapeutic window of VKAs should result in a significant improvement in quality of life and cost-savings.

As regards new parenteral anticoagulants, idraparinux or its biotinylated counterpart, SSR 126517, have the advantage of once-weekly administration. If higher dose SSR 126517 proves as effective and safe as conventional anticoagulation for treatment of PE, the drug could be used as an alternative to LMWH or fondaparinux for initial VTE treatment. Thus, a single subcutaneous injection of SSR 126517 could provide anticoagulation coverage while waiting for a therapeutic response with VKAs, simplifying the management of patients incapable of self injection. With once-weekly subcutaneous injection and no need for coagulation monitoring, SSR 126517 may also have a place in the long-term management of VTE provided that its efficacy and safety are confirmed in the phase III trials. However, the availability of shorter-acting oral factor Xa or thrombin inhibitors may limit the need for a long-acting parenteral agent.

The lack of safe rapidly-acting specific antidotes to reverse the anticoagulant effect remains a main challenge for the new anticoagulants. This is particularly problematic for drugs with a long half-life, such as idraparinux. Development of a biotinylated version of idraparinux may overcome this limitation provided that avidin, the antidote, is readily available and its safety established. Although not well studied, dialysis is likely to clear the direct factor Xa or thrombin inhibitors, all of which are small molecules.

In addition to assessing the antithrombotic efficacy and the haemorrhagic potential of these new agents, the experience with ximelagatran, an oral direct thrombin inhibitor that did not receive FDA approval because of hepatic toxicity, mandates careful attention to off-target side-effects. At present, it is unclear whether hepatic toxicity is unique to ximelagatran, or whether it represents a class effect. Ongoing studies with dabigatran etexilate and the oral factor Xa inhibitors will clarify this issue.

Although the new anticoagulants have been designed...
to be administered without coagulation monitoring, there are conditions where monitoring may be helpful to make appropriate dose adjustments. For example, monitoring may be needed in patients with hepatic or renal impairment or in those taking concomitant medications that may affect anticoagulant metabolism. How best to monitor the new anticoagulants is uncertain. SSR 126517 can be monitored using anti-factor Xa assays, but the tests must be performed using this drug as a standard. Specific kits have been studied and are ready to be commercialized, but data on usefulness and reliability of these measures are not available. Monitoring is at the moment more complicated for the oral factor Xa and thrombin inhibitors. These agents have variable effects on routine tests of coagulation, and none of these tests provide a good indication of drug levels. Factor Xa inhibition assays may prove useful to monitor oral factor Xa inhibitors. However, these assays have not been standardized and the therapeutic level is likely to vary among the different agents. Although the ecarin clotting time can be used to monitor dabigatran etexilate, the test is not available in all laboratories and has not been yet standardized. These issues will need to be addressed as the development of new anticoagulants moves forward.

Compliance with new anticoagulants may also be a critical issue because for some drugs and/or indications a twice-daily administration is required; moreover, compliance may be difficult to assess in the absence of routine coagulation monitoring. Finally, the cost of new anticoagulants may also be a potential obstacle on their usage, particularly if these drugs prove only to be as effective and safe as existing agents. Even with the added expense of coagulation monitoring, warfarin is relatively inexpensive; therefore, unless the cost of the new anticoagulants is relatively low, these drugs are likely to be reserved for patients who cannot be adequately controlled on warfarin, or for those without ready access to a laboratory. However, formal cost-effectiveness analyses are needed.

Even if the new drugs appear to be easier to use, anticoagulation clinics could still have a place in the management of anticoagulated patients for assessment of compliance, monitoring disease progress and determining the duration of anticoagulation; moreover, they could play an important role in monitoring off-target side-effects of the new drugs.

**Conclusions**

Current data suggest that both factor Xa and thrombin are good targets for new anticoagulants. Direct head-to-head comparison trials are needed to evaluate the relative benefit-to-risk ratios of the two classes of agents, but such studies are unlikely to be conducted in the near future. In the meantime, parallel clinical trial programs are ongoing to assess their efficacy and safety for the prevention and treatment of venous and arterial thromboembolism. Because of their pharmacologic properties, new anticoagulants represent an attractive alternative to the currently available drugs, and approval of one or more of these agents will lead to an improved drug armamentarium for the management of thromboembolic disorders. However, potential challenges of bringing new anticoagulants to the clinic should be taken into account.

**References**


370:949-56.


